On March 31, 2015 Infinity Pharmaceuticals reported that it has exercised its option to buy out all future royalty obligations due to Takeda for sales of duvelisib (IPI-145), Infinity’s dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in oncology indications (Press release, Infinity Pharmaceuticals, MAR 31, 2015, View Source [SID:1234502884]). The option was purchased in July 2014 for $5.0 million from a Takeda affiliate, and the exercise fee was $52.5 million. Exercising the option eliminates the future obligation to pay Takeda tiered royalties ranging from seven percent to 11 percent on worldwide net sales of duvelisib in oncology indications. Schedule your 30 min Free 1stOncology Demo! "Our decision to exercise this option underscores Infinity’s belief in the potential of duvelisib to be a first-in-class dual inhibitor of PI3K-delta,gamma for the treatment of a broad range of hematologic malignancies, or blood cancers, as we continue to advance our registration-focused studies in indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia," stated Adelene Perkins, Infinity’s chair, president and chief executive officer.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!